Optimal mitral annular and subvalvular shape change created by the coapsys device to treat functional mitral regurgitation

Kiyotaka Fukamachi*, Masahiro Inoue, Zoran Popović, Yoshio Ootaki, Michael W. Kopcak, Raymond Dessoffy, James D. Thomas, Patrick M. McCarthy

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


We have reported that the Myocor Coapsys (Myocor, Inc, Maple Grove, MN) device treated functional mitral regurgitation (MR) by reducing mitral annular dimension and repositioning papillary muscles. This study was conducted to evaluate the optimal Coapsys device sizing level. The Coapsys device was implanted in seven dogs after induction of MR by rapid ventricular pacing. The device consists of anterior and posterior pads connected by a subvalvular cord. The device was tightened in 5% increments of the left ventricular epicardial to epicardial dimension up to 40%. Hemodynamic and echocardiographic measurements were repeated at each tightening level. The Coapsys significantly reduced or eliminated functional MR, and the reduction was maximized at the 30% tightening level or lower in all cases. Although the left ventricular end diastolic volume decreased significantly, forward stroke volume was maintained until the 35% tightening level. The forward ejection fraction significantly increased from 33 ± 24% at baseline to 62 ± 42% at 40% tightening level. Mean aortic pressure decreased slightly but significantly. The Coapsys device can be applied over a broad range of tightening levels with significant reduction in MR without negative physiologic impact. This feature makes the device unusable in a variety of clinical settings.

Original languageEnglish (US)
Pages (from-to)17-21
Number of pages5
JournalASAIO Journal
Issue number1
StatePublished - Jan 1 2005

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Biomedical Engineering


Dive into the research topics of 'Optimal mitral annular and subvalvular shape change created by the coapsys device to treat functional mitral regurgitation'. Together they form a unique fingerprint.

Cite this